Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p15
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 15/16)
Character Range: 157846–160625

and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days' supply.
RANITIDINE in preparations supplied in the manufacturer's original pack containing not more than 14 days' supply except:
 (a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 14 dosage units; or
 (b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 7 dosage units.
SALICYLAMIDE except when included in Schedule 4.
SELENIUM in preparations for human therapeutic use except:
 (a) for topical use containing 3.5% or less of selenium sulfide;
 (b) when included in Schedule 4; or
 (c) for oral use with a recommended daily dose of 150 micrograms or less.
SILVER for therapeutic use except:
 (a) in solutions for human oral use containing 0.3% or less of silver when compliant with the requirements of the required advisory statements for medicine labels; or
 (b) in other preparations containing 1% or less of silver.
SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.
SODIUM NITRITE for therapeutic use (excluding when present as an excipient).
SQUILL except in preparations containing 1% or less of squill.
SULCONAZOLE in preparations for dermal use.
TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.
TETRACAINE in preparations for topical use other than eye drops, containing 10% or less of total local anaesthetic substances except in dermal preparations containing 2% or less of total local anaesthetic substances.
TETRACHLOROETHYLENE for human therapeutic use.
TETRYZOLINE.
THIABENDAZOLE for human therapeutic use.
TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.
TRAMAZOLINE.
TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:
 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 (b) in a day‑night pack containing triprolidine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
 except in preparations for the treatment of children under 2 years of age.
TUAMINOHEPTANE.
TYMAZOLINE.
XYLOMETAZOLINE.
ZINC CHLORIDE for human dermal use except in preparations containing 5% or less of zinc chloride.